VIRX vs. VYNE, CASI, THTX, ACXP, IPA, FBIO, XLO, NRXP, DARE, and BCTX
Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include VYNE Therapeutics (VYNE), CASI Pharmaceuticals (CASI), Theratechnologies (THTX), Acurx Pharmaceuticals (ACXP), ImmunoPrecise Antibodies (IPA), Fortress Biotech (FBIO), Xilio Therapeutics (XLO), NRx Pharmaceuticals (NRXP), Daré Bioscience (DARE), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.
VYNE Therapeutics (NASDAQ:VYNE) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
VYNE Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
Viracta Therapeutics has a net margin of 0.00% compared to Viracta Therapeutics' net margin of -6,710.38%. Viracta Therapeutics' return on equity of -77.46% beat VYNE Therapeutics' return on equity.
Viracta Therapeutics received 3 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. Likewise, 72.22% of users gave Viracta Therapeutics an outperform vote while only 57.50% of users gave VYNE Therapeutics an outperform vote.
In the previous week, Viracta Therapeutics had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 1 mentions for Viracta Therapeutics and 0 mentions for VYNE Therapeutics. Viracta Therapeutics' average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.36 indicating that VYNE Therapeutics is being referred to more favorably in the media.
VYNE Therapeutics has higher revenue and earnings than Viracta Therapeutics. Viracta Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are owned by institutional investors. 1.8% of VYNE Therapeutics shares are owned by insiders. Comparatively, 7.4% of Viracta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
VYNE Therapeutics currently has a consensus price target of $7.38, indicating a potential upside of 204.75%. Viracta Therapeutics has a consensus price target of $7.00, indicating a potential upside of 741.55%. Given VYNE Therapeutics' higher probable upside, analysts plainly believe Viracta Therapeutics is more favorable than VYNE Therapeutics.
Summary
VYNE Therapeutics and Viracta Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Viracta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viracta Therapeutics Competitors List
Related Companies and Tools
